npj Precision Oncology (Jul 2024)

Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance

  • Shengnan Chen,
  • Tao Hu,
  • Jikai Zhao,
  • Qian Zhu,
  • Jin Wang,
  • Zhan Huang,
  • Chan Xiang,
  • Ruiying Zhao,
  • Changbin Zhu,
  • Shun Lu,
  • Yuchen Han

DOI
https://doi.org/10.1038/s41698-024-00642-6
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Not all MET exon 14 skipping (METex14) NSCLC patients benefited from MET inhibitors. We hypothesized an inter-tumoral heterogeneity in METex14 NSCLC. Investigations at genomic and transcriptomic level were conducted in METex14 NSCLC samples from stage I-III and recurrent/metastatic patients as discovery and validation cohort. Four molecular subtypes were discovered. MET-Driven subtype, with the worst prognosis, displayed MET overexpression, enrichment of MET-related pathways, and higher infiltration of fibroblast and regulatory T cells. Immune-Activated subtype having the most idea long-term survival, had higher tertiary lymphoid structures, spatial co-option of PD-L1+ cancer cells, and GZMK+ CD8+ T cell. FGFR- and Bypass-Activated subtypes displayed FGFR2 overexpression and enrichments of multiple oncogenic pathways respectively. In the validation cohort, patients with MET-Driven subtype had better response to MET inhibitors than those with MET overexpression. Thus, molecular subtypes of METex14 NSCLC with distinct biological and clinical significance may indicate more precise therapeutic strategies for METex14 NSCLC patients.